Skip to content

EFFECT OF THE VITAMIN SUPPLEMENT DRINKS ON WORK PERFORMANCE - A DOUBLEBLIND, RANDOMIZED MULTIPLE DOSE TRIAL ON HEALTHY VOLUNTEERS

EFFECT OF THE VITAMIN SUPPLEMENT DRINKS ON WORK PERFORMANCE - A DOUBLEBLIND, RANDOMIZED MULTIPLE DOSE TRIAL ON HEALTHY VOLUNTEERS - EFFECT OF THE VITAMIN SUPPLEMENT DRINKS ON WORK PERFORMANCE - A DOUBLEBLIND, RANDOMIZED MULTIPLE DOSE TRIAL ON HEALTHY VOLUNTEERS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000003780
Enrollment
14
Registered
2010-06-19
Start date
2009-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy person

Interventions

1.a vitamin/taurine/caffeine(simple type) drink 2.a vitamin/taurine/caffeine/herb extracts(herb type) drink Duration of treatment: 5 days Total 10 days. 1.a vitamin/taurine/caffeine/herb extra

Sponsors

Keio University faculty of pharmacy
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Male and female between 20 and 35 years of age inclusive, at the time of signing the informed consent. Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests.

Exclusion criteria

Exclusion criteria: The subject has a known allergy to caffeine or alcohol. The subject has a known hypersensitivity to medical drugs. The subject usually uses simple or harbal type drinks.

Design outcomes

Primary

MeasureTime frame
Subjective :. selfreported questionnaires(Motivation, feeling of drowsiness, and fatigue) after 5 days administering. Objective: Kreapelin mental work test after 5 days administering.

Secondary

MeasureTime frame
Fatigue visual analog scale after 5 days administering. MFI20 after 5 days administering.

Countries

Japan

Contacts

Public ContactEmi Nakashima

Keio University faculty of pharmacy Division of pharmaceutics

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026